J. Goldman & CO LP Merus N.V. Transaction History

J. Goldman & CO LP

$3.53 Billion
Q4 2024

A detailed history of J. Goldman & CO LP transactions in Merus N.V. stock. As of the latest transaction made, J. Goldman & CO LP holds 7,001 shares of MRUS stock, worth $324,776. This represents 0.01% of its overall portfolio holdings.

Number of Shares

7,001

Previous 40,500 82.71%

Holding current value

$324,776

Previous $2.02 Million 85.47%

% of portfolio

0.01%

Previous 0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$41.45 - $54.5 $1.39 Million - $1.83 Million	-33,499 Reduced 82.71%	7,001 $294,000
Q3 2024 Nov 14, 2024	BUY	$47.19 - $58.84 $762,118 - $950,266	16,150 Added 66.32%	40,500 $2.02 Million
Q2 2024 Aug 14, 2024	BUY	$39.81 - $60.2 $163,221 - $246,820	4,100 Added 20.25%	24,350 $1.44 Million
Q1 2024 May 15, 2024	BUY	$28.03 - $51.82 $567,607 - $1.05 Million	20,250 New	20,250 $911,000
Q3 2022 Nov 14, 2022	SELL	$18.64 - $28.93 $2.24 Million - $3.48 Million	-120,214 Reduced 78.43%	33,063 $662,000
Q2 2022 Aug 15, 2022	BUY	$13.98 - $29.25 $1.43 Million - $2.99 Million	102,342 Added 200.93%	153,277 $3.47 Million
Q1 2022 May 16, 2022	BUY	$23.58 - $30.91 $568,820 - $745,641	24,123 Added 89.97%	50,935 $1.35 Million
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $536,240 - $865,759	26,812 New	26,812 $853,000
Q3 2021 Nov 15, 2021	SELL	$16.48 - $27.23 $1.33 Million - $2.19 Million	-80,600 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$20.0 - $25.48 $532,000 - $677,768	26,600 Added 49.26%	80,600 $1.7 Million
Q1 2021 May 17, 2021	BUY	$16.14 - $29.11 $871,560 - $1.57 Million	54,000 New	54,000 $1.13 Million

Others Institutions Holding MRUS

# of Institutions

202

Shares Held

60.7M

Call Options Held

111K

Put Options Held

85.7K

View Full List

About Merus N.V.

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.13B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

More about MRUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Account